2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6346 Representation of older patients in hematologic malignancy clinical trials: A retrospective analysis

Radhika Shah, MD, Salini Naidu, MD2, Anna Osipoff, MD3, Volodymyr Kodolov, MD4, Awa Keita-Manta, MD5
1 Premier Research, Morrisville, North Carolina, United States
2 Premier Research, Morrisville, North Carolina, United States
3 Premier Research, Morrisville, North Carolina, United States
4 Premier Research, Morrisville, United States
5 Premier Research, Morrisville, United States

Background: As the global population ages, the incidence of hematologic malignancies in older adults continues to rise.   Historically, opportunities for stem cell transplant (SCT) or chimeric antigen receptor T-cell (CAR-T) therapies have been limited for older patients due to concerns regarding treatment-related toxicity as well as comorbid conditions.   As a result, this group of patients 75 years or older is underrepresented in cancer trials, despite the growing need for evidence-based treatment decisions for these patients. Despite the FDA’s mandate to encourage inclusion of older patients in oncology trials, this continues to be a challenge.  

 

Methods: A retrospective review of 52 hematologic malignancy clinical trials published between 2010-2025 was conducted, comprised of 20 CAR-T, 18 SCT/HSCT, 13 ASCT, and 1 allo-HSCT study. Hematologic malignancies included multiple myeloma (MM), AML, ALL, CLL, Lymphomas, MDS.Trial eligibility criteria and participant age characteristics were evaluated to assess trends in age inclusivity, efficacy, and feasibility trends.   i 

 

Results: Reporting of older adult representation was inconsistent.  Median age was reported in 96.2% of studies, but only 63.5% reported participants aged ≥65 years and 50.0% those aged >75 years. Enrolled populations remained relatively young, with a typical median age of about 58 years. Use of upper age limits declined sharply from 100% of trials in 2006-2010 to 30% in  2021-2026 reflecting more inclusive eligibility criteria. Yet, despite fewer age restrictions, participant age remained unchanged over time (R² = 0.0013).). Enrollment of patients aged ≥65 years increased only modestly (R² = 0.0528), while enrollment of those aged >75 years showed minimal improvement (R² = 0.0156), indicating persistent underrepresentation of the oldest adults. Among the few studies reporting median overall survival (OS) data, inclusion of older participants was not associated with inferior outcomes.  

 

Conclusion: Although age-related concerns such as physiological decline and comorbidity burden have historically constrained inclusion of older patients in clinical trials, hematologic malignancy trials are now beginning to challenge traditional age cutoffs. Advances in supportive care, conditioning regimen modification, and patient stratification have facilitated broader inclusion of older adults; however, these improvements have not yet translated into substantial increases in enrollment among the oldest age groups. Patients aged ≥65 years remain underrepresented, and those aged >75 years continue to be markedly excluded. This suggests that eliminating upper age limits alone does not meaningfully increase participation, as additional barriers beyond eligibility criteria continue to limit enrollment of older adults. The next steps needed are to address these gaps through age-inclusive trial design as a recruitment strategy, which is essential to meet the needs of an aging cancer population. 

 

Radhika Shah, MD: No relevant conflicts of interest to declare.